TB-500: Mechanism, Safety, and Regulatory Overview
TB-500: Mechanism, Safety & Regulatory Guide
The content on this page is for general informational and educational purposes only and is not intended as medical advice, a recommendation, or an endorsement of any specific medication, treatment, or health product. Always consult a qualified healthcare provider before making decisions about medications, supplements, or changes to your health regimen. BodySpec does not prescribe, dispense, promote, offer, sell, or facilitate access to any of the pharmaceutical products discussed below.
Have you ever wondered how a fragment of a naturally occurring protein might speed up tissue repair—despite no human trials to back it?
TB-500 is a synthetic heptapeptide (a peptide composed of seven amino acids) fragment of thymosin beta-4, catalogued under PubChem CID 62707662 (PubChem, 2026). Early animal and in vitro studies have investigated its potential for wound healing, cell migration, and angiogenesis.
Yet while early data hint at real potential, teasing apart TB-500’s cellular actions and its evolving legal status calls for a closer look.
What Is TB-500?
Thymosin beta-4 is an endogenous, 43-amino acid protein that regulates actin dynamics—the processes that control cell movement and structure—and supports wound repair (UniProt, 2026). TB-500 is a 7-amino acid peptide fragment (Ac-LKKTETQ) representing the protein’s core actin-binding domain. It has a molecular weight of 889.0 g/mol and the formula C38H68N10O14 (PubChem, 2026). In the few published animal studies, TB-500 has been injected intraperitoneally, and its tissue distribution has not been characterized.
Mechanism of Action: Actin Modulation & Tissue Repair
A scoping review by McGuire et al. (2026) mapped the mechanisms studied for thymosin beta-4 (TB4) and TB-500, finding direct TB-500 evidence in only one of its 80 included studies:
- Enhancing endothelial cell migration.
- Promoting angiogenesis (the formation of new blood vessels), which may support oxygen and nutrient delivery to injury sites.
- Modulating inflammatory signaling.
Potential Benefits & Preclinical Evidence
Preclinical models suggest TB-500 may support tissue repair:
- Improves early Achilles tendon healing in rats (Biçer et al., 2026); muscle data are specific to full-length thymosin beta-4.
- Shows wound-healing activity in vitro for the metabolite Ac-LKKTE, not TB-500 itself (Rahaman et al., 2024).
Despite these findings, no controlled human interventional trials have evaluated the TB-500 fragment (Ac-LKKTETQ) itself; the human trial data that exist are for full-length thymosin beta-4.
Dosage Considerations
No standardized human dosing guidelines exist for TB-500. In the one controlled rodent study, rats received TB-500 at 60 µg/kg/day intraperitoneally for four weeks (Biçer et al., 2026). Higher milligram-per-kilogram figures sometimes quoted come from studies of full-length thymosin beta-4, a different molecule. Any human regimen remains speculative—patients should consult a qualified healthcare provider before considering experimental frameworks.
Regulatory Status & Compliance
- The FDA listed TB-500 in 503A Category 2 in late 2023; it was removed in April 2026 and remains ineligible for compounding (BSCG, 2026).
- WADA prohibits TB-500 under section S2.3 (Growth Factors and Growth Factor Modulators) (World Anti-Doping Agency, 2026).
- Military and collegiate drug-testing programs prohibit TB-500 under their own rules—the NCAA names it explicitly, and unapproved drugs require a prescription.
Ensuring Peptide Purity: Quality-Control Checklist
- Certificate of Analysis confirming ≥ 95% purity.
- Third-party testing for endotoxins, heavy metals, and microbial contaminants.
- Certification through accredited programs such as BSCG Certified Drug Free.
- Batch-specific HPLC or mass spectrometry chromatograms verifying sequence integrity.
- Clear storage and handling instructions on labeling.
TB-500 vs. BPC-157 vs. Other Peptides
| Feature | TB-500 | BPC-157 | Other Peptides |
|---|---|---|---|
| Mechanism | Actin modulation, angiogenesis | VEGF modulation, gut mucosal repair | Varies by compound |
| Clinical Evidence | Preclinical only | Animal studies, limited case reports | Minimal human data |
| Regulatory Status | Unapproved; removed from FDA Cat 2 | Research chemical (unapproved) | Largely research chemicals |
| WADA Prohibition | S2.3 Growth Factor Modulator | S0 Non-Approved Substance | Depends on classification |
| Primary Uses | Tissue repair, wound healing | GI issues, tendon/ligament recovery | Research, experimental |
Frequently Asked Questions
Is TB-500 legal for athletes? TB-500 is banned by WADA; athletes face sanctions for positive tests.
Are there human safety data? No controlled human trials have assessed TB-500’s safety profile.
What drives its wound-healing effects? An in vitro study suggests the metabolite Ac-LKKTE may be active (Rahaman et al., 2024).
Could TB-500 cause tumor growth? Thymosin beta-4 is overexpressed in colorectal cancer, correlating with metastasis and worse survival; relevance to TB-500 remains undetermined (Lee et al., 2017).
Where can I learn more about recovery protocols? See our guides on Soft Tissue Injury: Symptoms, Treatment, and Recovery and Muscle Recovery: A Science-Backed Guide to Heal Faster.
Conclusion
TB-500 remains an intriguing research chemical with preliminary preclinical support for promoting cellular migration and vascular repair pathways, yet it lacks human clinical validation and clear therapeutic approval. For those interested in understanding their body composition independent of peptide protocols, BodySpec DEXA scans offer precise, reproducible measurements of lean mass index, bone density, and overall body composition. Schedule a scan to establish an accurate baseline for your body composition journey.